Of note, the restoration of FXN protein expression in gene-edited microglia, achieved by excision of GAA repeats in the FXN gene, attenuated this hyperinflammatory microglia phenotype, highlighting the potential of CRISPR/Cas9-based therapies to target microglia activation in FRDA pathology. Here, FXN is linked to Friedreich ataxia.